A cost-effectiveness analysis of respiratory syncytial virus (RSV) prophylaxis in infants in the United Kingdom

Health Economics Review

Table 2 Average age and weight at treatment initiation

Subgroup	Post conception age at birth (SE)	Chronological age at start of administration (SE)	Adjusted chronological age*	Weight in g (upper and lower CI)
CHD babies^§	38.50 (0.10)^‡	26.60 (0.8)	25.10	6,649 (6,257; 7,041)
CLD babies	29.00 (0.11)^‡	23.12 (0.68)	14.13	4, 833 (4,084; 4,527)
Preterm: <29 wGA	29.00 (3.70^†)^‡	15.40 (0.51)	4.40	3,709 (3,503; 3,915)
Preterm: 29–32 wGA	30.50 (3.89^†)^‡	12.39 (0.34)	2.89	3,959 (3,804; 4,114)
Preterm: 33–35 wGA	34.00 (4.34^†)^‡	10.89 (0.46)	4.89	4,306 (4,084; 4,527)

Abbreviations: CI Confidence interval, SE Standard error, CHD Congenital heart disease, CLD Chronic lung disease, wGA weeks of gestational age. * Calculated assuming a normal gestation of 40 weeks; ^† Estimated assuming a confidence interval of ± 25%; ^‡ Gamma distribution; ^§ Data from Feltes et al. 2003 [4] or MedImmune Data on File.

ISSN: 2191-1991